The United States Food and Drug Administration (FDA) has approved UCB's Cimzia (certolizumab pegol) injection intended for the treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis, with objective signs of inflammation, it was reported on Friday.
The efficacy of the product was studied in a randomised clinical trial in 317 adult patients with non-radiographic axial spondyloarthritis with objective signs of inflammation, indicated by elevated C-reactive protein (CRP) levels and/or sacroiliitis (inflammation of the sacroiliac joints) on MRI.
Nikolay Nikolov, MD, associate director for rheumatology of the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA's Center for Drug Evaluation and Research, said, Today's approval of Cimzia fulfils an unmet need for patients suffering from non-radiographic axial spondyloarthritis as there has been no FDA-approved treatments until now.'
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China